Impact of Supplementation with Omega‑3 in the Prevention of Contrast‑Induced Nephropathy Following Elective Percutaneous Coronary Intervention in Patients with Chronic Kidney Disease: A Randomized Placebo‑Controlled Trial

Farzaneh Foroughinia, Elnaz Rohani Rad

Abstract


Background: Anti‑oxidants were investigated in several studies as a preventive strategy for prevention of contrast‑induced nephropathy (CIN). Omega‑3 polyunsaturated fatty acids have antioxidant properties; however, their role in the prevention of CIN is still unknown. Therefore, in this study, we aimed to evaluate the efficacy of omega‑3 supplementation in the prevention of contrast‑induced nephropathy following elective percutaneous coronary intervention in patients with chronic kidney disease.

Methods: This is a double‑blinded and randomized clinical trial. Eighty eligible patients with glomerular filtration rate of 30‑60 mL/min/1.73 m2, scheduled to undergo elective PCI, were randomly divided into omega‑3 (a single dose of 2500 mg omega‑3 12 hours before PCI plus hydration therapy) or control (placebo plus hydration therapy) groups. Blood specimens for measuring serum creatinine and cystatin C were collected from each patient at baseline and 24 h after PCI.

Results: Omega‑3 did not show any significant effect on post‑PCI serum creatinine and cystatin C compared to the controls. In addition, serum creatinine analysis showed that CIN occurred in 6 (16.2%) patients of the omega‑3 and 4 (9.3%) patients of the control group (P = 0.50).

Conclusions: Our results could not support the protective effect of a single dose of omega‑3 in decreasing serum creatinine, serum cystatin C, and the incidence of CIN in patients with CKD undergoing PCI. To better evaluate the effect of omega‑3, future studies with higher and/or multiple doses of omega‑3 are highly recommended.


Keywords


Chronic; contrast‑induced nephropathy; creatinine; cystatin C; fatty acids; omega‑3; renal insufficiency

Full Text:

PDF

References


Schweiger MJ, Chambers CE, Davidson CJ, Zhang S, Blankenship J, Bhalla NP, et al. Prevention of contrast induced nephropathy: Recommendations for the high risk patient undergoing cardiovascular procedures. Catheter Cardiovasc Interv 2007;69:135‑40.2. Mehran R, Nikolsky E. Contrast‑induced nephropathy: Definition, epidemiology, and patients at risk. Kidney Int Suppl 2006;100:S11‑5.3. Goldenberg I, Matetzky S. Nephropathy induced by contrast media: Pathogenesis, risk factors and preventive strategies. CMAJ 2005;172:1461‑71.4. Morcos S, Thomsen H, Webb J. Contrast‑media‑induced nephrotoxicity: A consensus report. Eur Radiol 1999;9:1602‑13.

McCullough PA. Contrast‑induced acute kidney injury. J Am Coll Cardiol 2008;51:1419‑28.6. Jorgensen AL. Contrast‑induced nephropathy: Pathophysiology and preventive strategies. Crit Care Nurse 2013;33:37‑46.7. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta‑analysis. Am J Kidney Dis 2002;40:221‑6.8. Dvoršak B, Kanič V, Ekart R, Bevc S, Hojs R. Ascorbic acid for the prevention of contrast‑induced nephropathy after coronary angiography in patients with chronic renal impairment: A randomized controlled trial. Ther Apher Dial 2013;17:384‑90.9. Xu R, Tao A, Bai Y, Deng Y, Chen G. Effectiveness of N‑acetylcysteine for the prevention of contrast‑induced nephropathy: A systematic review and meta‑analysis of randomized controlled trials. J Am Heart Assoc 2016;5. pii: e003968.10. Liu J, Xie Y, He F, Gao Z, Hao Y, Zu X, et al. Recombinant brain natriuretic peptide for the prevention of contrast‑induced nephropathy in patients with chronic kidney disease undergoing nonemergent percutaneous coronary intervention or coronary angiography: A randomized controlled trial. Biomed Res Int 2016;2016:5985327.11. Hassan IR, Gronert K. Acute changes in dietary ω‑3 and ω‑6 polyunsaturated fatty acids have a pronounced impact on survival following ischemic renal injury and formation of renoprotective docosahexaenoic acid‑derived protectin D1. J Immunol 2009;182:3223‑32.12. Prasad PV, Priatna A, Spokes K, Epstein FH. Changes in intrarenaloxygenation as evaluated by BOLD MRI in a rat kidneymodel for radiocontrast nephropathy. J Magn Reson Imaging 2001;13:744‑7.13. Bakris GL, Lass N, Gaber AO, Jones JD, Burnett JC Jr. Radiocontrastmedium‑induced declines in renal function: A role foroxygen free radicals. Am J Physiol 1990;258:F115‑20.14. Solomon R. Preventing contrast‑induced nephropathy: Problems, challenges and future directions. BMC Med 2009;7:24.15. Foroughinia F, Salamzadeh J, Namazi MH. Protection from procedural myocardial injury by omega‑3 polyunsaturated fatty acids (PUFAs): Is related with lower levels of creatine kinase‑MB (CK‑MB) and troponin I? Cardiovasc Ther 2013;31:268‑73.16. Foroughinia F, Foroozmehr M. Effect of pretreatment with omega‑3 supplement on cardiac necrosis markers in chronic kidney disease patients undergoing elective percutaneous coronary intervention. J Res Pharm Pract 2017;6:94‑9.17. Fassett RG, Gobe GC, Peake JM, Coombes JS. Omega‑3 polyunsaturated fatty acids in the treatment of kidney disease. Am J Kidney Dis 2010;56:728‑42.18. Donadio JV, Grande JP. The role of fish oil/omega‑3 fatty acids in the treatment of IgA nephropathy. Semin Nephrol 2004;24:225‑43.19. Bennett W, Walker R, Kincaid‑Smith P. Treatment of IgA nephropathy with eicosapentanoic acid (EPA): A two‑year prospective trial. Clin Nephrol 1989;31:128‑31.20. Foroughinia F, Namazi MH, Salamzadeh J. Study of the effect of omega‑3 polyunsaturated fatty acids (PUFAs) on inflammatory marker C‑reactive protein (CRP) following elective percutaneous coronary intervention (PCI). IJPS 2012;8:39‑45.21. Foroughinia F, Movahed Nouri B, Kujuri J, Ostovan MA. Impact of omega‑3 supplementation on high sensitive C‑reactive protein level and 30‑day major adverse cardiac events after the implementation of coronary stent in patients with chronic kidney disease: A randomized clinical study. Adv Pharm Bull 2018;8:471‑8.22. Foroughinia F, Mirjalili M, Mirzaei E, Oboodi A. Omega‑3 supplementation in the prevention of contrast induced nephropathy in patients undergoing elective percutaneous coronary intervention: A randomized placebo‑controlled trial. Adv Pharm Bull 2019;9:307‑313.23. Firouzi A, Eshraghi A, Shakerian F, Sanati HR, Salehi N, Zahedmehr A, et al. Efficacy of pentoxifylline in prevention of contrast‑induced nephropathy in angioplasty patients. Int Urol Nephrol 2012;44:1145‑9.24. Pezeshgi A, Parsamanesh N, Farhood G, Mahmoodi K. Evaluation of the protective effect of N‑acetylcysteine on contrast media nephropathy. J Renal Inj Prev 2015;4:109‑12.